PHASE-II STUDY OF MITOGUAZONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE FOR PATIENTS WITH DIFFUSE HISTOLOGIC SUBTYPES OF NON-HODGKINS-LYMPHOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY (PE481)

Mitoguazone, an investigational agent with significant activity in adv anced lymphoma, was added to a modified CHOP regimen (COPA) in an effo rt to improve the activity of standard therapy in 66 previously untrea ted patients with stages II-IV lymphoma and diffuse histology of inter mediate or high grade other than lymphoblastic in this phase II pilot study. The regimen was well tolerated and the complete response rate i n diffuse large cell lymphoma was 55%. Sixty-five percent of all compl ete responders were in complete response for at least one year. Despit e these excellent results, it is unlikely that the addition of mitogua zone improved results compared with those obtained with standard thera py alone, since similar results have been frequently reported with the latter.